NKG2A blocking antibody

An NKG2A blocking antibody is a type of monoclonal antibody designed to target and block the natural killer group 2 member A (NKG2A) receptor, an inhibitory checkpoint receptor expressed on natural killer (NK) cells and a subset of cytotoxic CD8+ T cells. NKG2A forms a heterodimer with CD94 and binds to its ligand, human leukocyte antigen E (HLA-E), which is frequently overexpressed on various tumor cells. This interaction transmits inhibitory signals that suppress the cytotoxic activity of NK and T cells, allowing tumors to evade immune surveillance. By blocking the NKG2A/CD94-HLA-E interaction, NKG2A blocking antibodies unleash the anti-tumor effector functions of these immune cells. Several NKG2A blocking antibodies, such as monalizumab, BMS-986315, and S095029, are being evaluated in clinical trials, often in combination with other immune checkpoint inhibitors (like PD-1/PD-L1 blockers) or tumor-targeting antibodies to enhance anti-cancer efficacy.

Other names

NKG2A antibodyNKG-2A antibodyNKG 2A antibodyNKG2A blockerNKG-2A blockerNKG 2A blockerNKG2A inhibitorNKG-2A inhibitorNKG 2A inhibitorNKG2A-blocking antibodyNKG-2A-blocking antibodyNKG 2A-blocking antibodyNKG2A-blocking monoclonal antibodyNKG-2A-blocking monoclonal antibodyNKG 2A-blocking monoclonal antibodyanti-NKG2A antibodyanti-NKG-2A antibodyanti-NKG 2A antibodyanti-NKG2A monoclonal antibodyanti-NKG-2A monoclonal antibodyanti-NKG 2A monoclonal antibody